EU Committee Backs Collective Drug Price Talks, Early-Warning System For Shortages
A report beefing up the proposals contained in the European Commission’s Pharmaceutical Strategy has been approved by an influential parliamentary committee that wants to see a “stable, updated and safety-centered regulatory system” and an "autonomous and resilient" pharmaceutical industry.
You may also be interested in...
EU Legislators Firm Up Commission’s Plans To Overhaul Pharma Rules
Efforts to overhaul the EU pharmaceutical legislation have been given added impetus after the European Parliament called for action to boost innovation and medicines access, shore up manufacturing and supply chains, and examine the link between R&D spending and drug prices.
EFPIA On Why More EU Drug Price Transparency Isn’t The Answer
As discussions continue over the European Commission’s plans to overhaul the EU pharmaceutical legislation, the R&D-based pharma industry body EFPIA says that any new pharma policy framework will need to be stable, fast, effective and globally competitive.
European Commission Steps Further Towards ‘Ambitious’ Pharma Legislation Reform
The incentives system, access to medicines, future proofing for novel products and antimicrobial resistance are just some of the topics included in a new consultation.